Jamie Cheung
Research Subjects
Research Interests
Jamie Cheung has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- James R. Berenson
Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
2 shared publications Aaron Gette
QOL San Jose California USA
1 shared publicationAlex Wright
QOL San Jose California USA
1 shared publication- Anirvin Bommaraju
Berenson Cancer Center West Hollywood California USA
1 shared publication Blake Morrison
QOL San Jose California USA
1 shared publicationFrank Pezzullo
QOL San Jose California USA
1 shared publication
Latest Publications
- Open Access
- 16 November 2026
- Published by Wiley in British Journal of Haematology
A real‐time text‐based assessment tool for monitoring symptoms and quality of life for multiple myeloma patients: A feasibility study
Summary: Patient‐reported outcome (PRO) and quality of life (QoL) assessments for multiple myeloma (MM) patients are traditionally collected at infrequent intervals using burdensome instruments, resulting in limited clinical visibility between visits. This creates a critical gap in care, as evolving symptoms and treatment‐related toxicities frequently occur outside scheduled encounters and may remain unrecognized. A single‐centre pilot study evaluated the feasibility and clinical utility of a short message service (SMS)‐based remote monitoring platform, assessing 8 symptoms and 10 QoL domains for 58 MM patients over 90 days. End‐points included feasibility and engagement measured using completion rates, time burden and identification of clinically actionable events. A total of 1604 assessments were delivered, with an overall completion rate of 85.5%, and 72.4% of participants achieving >80% completion rate. Median completion time was 1.80 min. During the 90‐day study period, 215 predefined alerts were generated, of which 101 (47.0%) prompted clinical intervention within 48 h, frequently occurring outside routine clinic visits. SMS‐based remote monitoring demonstrated high feasibility, sustained engagement and minimal patient burden. This platform enabled real‐time identification of symptoms and facilitated rapid follow‐up by clinicians, supporting its potential for remote therapeutic monitoring rather than a passive data collection tool.
- 16 November 2026
- Published by Wiley in British Journal of Haematology
Open AccessA real‐time text‐based assessment tool for monitoring symptoms and quality of life for multiple myeloma patients: A feasibility study
Summary: Patient‐reported outcome (PRO) and quality of life (QoL) assessments for multiple myeloma (MM) patients are traditionally collected at infrequent intervals using burdensome instruments, resulting in limited clinical visibility between visits. This creates a critical gap in care, as evolving symptoms and treatment‐related toxicities frequently occur outside scheduled encounters and may remain unrecognized. A single‐centre pilot study evaluated the feasibility and clinical utility of a short message service (SMS)‐based remote monitoring platform, assessing 8 symptoms and 10 QoL domains for 58 MM patients over 90 days. End‐points included feasibility and engagement measured using completion rates, time burden and identification of clinically actionable events. A total of 1604 assessments were delivered, with an overall completion rate of 85.5%, and 72.4% of participants achieving >80% completion rate. Median completion time was 1.80 min. During the 90‐day study period, 215 predefined alerts were generated, of which 101 (47.0%) prompted clinical intervention within 48 h, frequently occurring outside routine clinic visits. SMS‐based remote monitoring demonstrated high feasibility, sustained engagement and minimal patient burden. This platform enabled real‐time identification of symptoms and facilitated rapid follow‐up by clinicians, supporting its potential for remote therapeutic monitoring rather than a passive data collection tool.
- Open Access
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 410-416
Treatment with Daratumumab in Combination with Glucocorticosteroids as First-Line Treatment Achieves a Complete Remission for a Patient with Multiple Myeloma and Resolves Neutropenia: A Case Report
Introduction: Multiple myeloma (MM) is a bone marrow malignancy of plasma cells that can be treated with monoclonal antibodies (mAbs) including daratumumab. This mAb binds to CD38 proteins expressed on MM cells, allowing the immune system to recognize and kill these tumor cells. Neutropenia is a common complication in MM, often attributed to the disease itself or treatment with agents such as immunomodulatory drugs. However, its resolution with first-line mAb therapy has not previously been reported. Case Presentation: We report a case of a 32-year-old Filipino female with smoldering MM. She developed neutropenia and as a result was treated with a combination of daratumumab and glucocorticosteroids. She achieved a complete remission (CR), and her absolute neutrophil count normalized. The treatment was well tolerated with no adverse effects reported, and the patient remains in CR after more than 3 years of therapy. Discussion: This case highlights the potential for daratumumab combined with glucocorticosteroids alone to effectively manage a patient’s MM and severe neutropenia, suggesting a dual therapeutic benefit without treatment-related toxicity. Our findings support the consideration of daratumumab and glucocorticosteroids as a viable first-line therapeutic option for patients with MM who develop neutropenia.
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 410-416
Open AccessTreatment with Daratumumab in Combination with Glucocorticosteroids as First-Line Treatment Achieves a Complete Remission for a Patient with Multiple Myeloma and Resolves Neutropenia: A Case Report
Introduction: Multiple myeloma (MM) is a bone marrow malignancy of plasma cells that can be treated with monoclonal antibodies (mAbs) including daratumumab. This mAb binds to CD38 proteins expressed on MM cells, allowing the immune system to recognize and kill these tumor cells. Neutropenia is a common complication in MM, often attributed to the disease itself or treatment with agents such as immunomodulatory drugs. However, its resolution with first-line mAb therapy has not previously been reported. Case Presentation: We report a case of a 32-year-old Filipino female with smoldering MM. She developed neutropenia and as a result was treated with a combination of daratumumab and glucocorticosteroids. She achieved a complete remission (CR), and her absolute neutrophil count normalized. The treatment was well tolerated with no adverse effects reported, and the patient remains in CR after more than 3 years of therapy. Discussion: This case highlights the potential for daratumumab combined with glucocorticosteroids alone to effectively manage a patient’s MM and severe neutropenia, suggesting a dual therapeutic benefit without treatment-related toxicity. Our findings support the consideration of daratumumab and glucocorticosteroids as a viable first-line therapeutic option for patients with MM who develop neutropenia.